bioAffinity Technologies (BIAF) Liabilities and Shareholders Equity (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $7.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 43.23% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $35.2 million (up 39.31% YoY), while the FY2025 annual figure was $11.0 million, up 68.27% from the prior year.
• Liabilities and Shareholders Equity eased to $7.9 million in Q1 2026 per BIAF's latest filing, from $11.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $14.1 million in Q3 2022 and bottomed at $4.8 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $8.8 million across 5 years, with a median of $8.2 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 738.23% — and 2024, when it plunged 35.7%.
• bioAffinity Technologies' Liabilities and Shareholders Equity stood at $12.2 million in 2022, then sank by 32.51% to $8.2 million in 2023, then declined by 20.77% to $6.5 million in 2024, then soared by 68.27% to $11.0 million in 2025, then fell by 27.51% to $7.9 million in 2026.
• Business Quant data shows BIAF's Liabilities and Shareholders Equity at $7.9 million in Q1 2026, $11.0 million in Q4 2025, and $11.5 million in Q3 2025.